CHMP Backs Zokovea for COVID-19 Post-Exposure

Key Takeaways

• CHMP recommended Zokovea (ensitrelvir) for COVID-19 PEP in people aged 12+.
• Benefit cited: lower symptomatic COVID-19 risk in household contacts started within 72 hours of index symptom onset.
• Product form: 125 mg tablets; applicant Shionogi B.V.
• Common adverse reactions listed: hypertriglyceridaemia, headache, diarrhoea and nausea.

Zokovea CHMP opinion at a glance

Field	Detail
Product	Zokovea (ensitrelvir)
Applicant	Shionogi B.V.
Regulator action	CHMP positive opinion (23 July 2026)
Indication sought	COVID-19 post-exposure prophylaxis, ages 12+
Mechanism	Selective SARS-CoV-2 3C-like protease inhibition
Key evidence	Multicentre double-blind RCT in household contacts (SCORPIO-PEP / NCT05897541)
Next step	European Commission marketing authorisation decision

What did CHMP recommend?

EMA's Zokovea overview states that on 23 July 2026 CHMP adopted a positive opinion recommending marketing authorisation for post-exposure prophylaxis of COVID-19. The full indication text is: Zokovea is indicated for the post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older, and should be used in accordance with official recommendations.

Primary sources: EMA Zokovea EPAR overview and the CHMP summary of positive opinion PDF.

What clinical benefit did EMA cite?

EMA said the benefit is a reduced risk of symptomatic COVID-19 in household contacts of an individual with COVID-19 when administered within 72 hours after index patient symptom onset, observed in a multicentre, double-blind, randomised, placebo-controlled efficacy and safety study. Ensitrelvir acts through selective inhibition of the SARS-CoV-2 3C-like protease, thereby inhibiting viral replication. The product will be available as 125 mg tablets.

Trial registration for the PEP programme: ClinicalTrials.gov NCT05897541 (SCORPIO-PEP).

What safety points are listed so far?

The CHMP opinion summary lists hypertriglyceridaemia, headache, diarrhoea and nausea among the most common side effects. Detailed recommendations will appear in the SmPC after Commission authorisation. Drug-interaction cautions typical of CYP3A-interacting antivirals are expected to feature prominently once labelling is final.

July context: EMA CHMP meeting highlights 20–23 July 2026.

How could PEP change European COVID pathways?

Oral post-exposure options have been limited as monoclonal antibody combinations aged out against evolving variants. An authorised protease-inhibitor PEP for household contacts could support outbreak control guidance if member-state recommendations adopt it. Timing from exposure and test-negative status at baseline will matter for operational protocols.

What should public-health and clinical teams watch?

• Final dosing schedule and start-window language in the SmPC
• CYP3A / transporter interaction tables and contraindicated medicines
• Pregnancy and paediatric adolescent precautions
• How national guidance positions Zokovea versus vaccines, isolation and treatment antivirals

A CHMP opinion is not yet EU-wide authorisation; Commission timing is typically measured in weeks after opinion adoption.

What remains uncertain?

Variant-specific effectiveness, real-world adherence within the 72-hour window, and reimbursement for asymptomatic contacts remain open. Literature summaries such as PubMed's ensitrelvir PEP record should be read alongside the final EU label rather than substituted for it.

Related NovaPharma coverage

• CHMP July 2026: 12 New Medicines Recommended
• EMA Recommends Susvimo Implant for Wet AMD
• EC Approves Wegovy Pill, First Oral GLP-1 in EU

Frequently Asked Questions

Primary Sources

1. EMA: Zokovea EPAR overview
2. EMA: CHMP summary of positive opinion for Zokovea (PDF)
3. ClinicalTrials.gov: SCORPIO-PEP NCT05897541
4. EMA: CHMP meeting highlights 20–23 July 2026